thegoodfellas/blogset-br huggingface dataset:
the organism. Cells that have received this new gene multiply, perpetuating the novelty in the body. This exchange of DNA can function as an effective treatment for hereditary diseases as in the case of the Briton Rhys."It is as if the tape of the genome was a zipper with a tooth missing. A way to fix the problem is to put a cellophane tape in place of the tooth that is missing. Thus, the zipper back to close more easily, although it doesn't slip perfect way. The correction mechanism is gene therapy. The durex itself is altered gene inserted into the cell, "said Mayana Zatz, geneticist at the University of Sao Paulo (USP) and columnist for VEJA website.April 2002. The only hope of Rhys Evans was a virus. Bearer of the syndrome of severe combined immunodeficiency (SCID), also known as bubble boy disease, Britain 's, then 18 months, received an injection into a vein containing a virus that carried a gene altered in the laboratory. Upon entering the bloodstream of Evans, the microorganism linked to bone marrow cells. Hurled into the core, the new gene began, then, to change the orders for which the Defense cells to be produced.Currently, Rhys Evans still depends on daily and weekly injections of drugs to stay healthy. But gene therapy, a novelty that seemed science fiction at the time, saved the life of the boy patients with SCID usually live for only two years. Now, ten years after the pioneering treatment, the European Medicines Agency (EMA) has approved the first gene therapy on the continent, the first in the world outside of China (where the accuracy with this type of research is still not so great). The Glybera, name of therapy, is intended for patients suffering from a rare disease that causes inflammation in the pancreas.Pioneering Treatment There are now more than 50,000 research into gene therapy listed by PubMed, online database of health research. Still, only three treatments made with gene therapy are released for use on the planet. Two from China and one by the European Union. Approved in July this year by EMA, Glybera is an adenovirus that encodes lipoprotein lipase for treatment of patients with deficiency in the production of the enzyme. This rare condition is characterized by bouts of severe pancreatitis or multiple.The disease is caused by a genetic mutation that prevents the production of the enzyme, needed to break the fat particles in the blood, which form after meals. Without this enzyme, the fat can accumulate so much that the color of blood arrives to get a little whitish. Patients with this condition are more susceptible to having bouts of inflammation in the pancreas. Currently, the only available treatment is a diet extremely low in fat. In dealing with the body are inserted Glybera the patient correct copies of the gene responsible for the production of lipoprotein lipase. According to EMA, a unique treatment, which consists in the injection in various points of the leg muscles, can cause a production even partial enzymes for several years. The patient is not
enough, however, to the State considered normal fat break. He manages to produce, however, sufficient amounts of the enzyme so that it can live with more quality of life.In addition to the treatment of diseases, gene therapy could improve the human body. Experts from the National Cancer Research Centre (CNIO, its acronym in Spanish), in Spain, showed that the longevity of animals can be increased with genetic therapy applied in adulthood. In tests, the researchers used adult mice (one year of age) and seniors (two years old). After receiving the gene therapy, the first group lived, on average, by 24% longer, while the older mice had a 13% increase in life expectancy. Besides longevity, reported the study, animal health has improved considerably, delaying the onset of age-related diseases, such as osteoporosis and insulin resistance, and keeping any longer functions such as neuromuscular coordination.Other research, developed at Cornell University, in the United States, and tested in mice, can in the future to end the addiction to nicotine. The treatment changes the patient's liver genes, so that it will produce antibodies that attack "the nicotine, preventing her to connect to the brain's pleasure receptors.Diseases without cures Although gene therapy is a promising treatment for various diseases, mostly hereditary and some types of cancer, is a major barrier to large-scale use. According to geneticist Mayana Zatz, the technology is not sharp enough to have absolute control over the insertion of this gene. Science can't yet predict with certainty that it will work correctly. In case of errors in the substitution of genes, or even when a material does not integrate into the genome, serious health problems can occur. There is a risk of developing tumors, for example, or a very strong immune response, dangerous to the body. Because of little technique, the therapy is being tested in diseases without a cure. And still faces difficulties to leave the laboratory. "If someone manages to get along well with certain condition, why take the risk with gene therapy?", says Charles Frederick Menck, genetic specialist and professor at the Institute of Biomedical Sciences (ICB).In some cases, the therapeutic effects may be transitory unexpectedly, as in the case of a survey conducted by doctor Renato Kalil, of the Institute of Cardiology of Rio Grande do Sul, in 2009. The cardiologist has been able to increase the number of blood vessels in the heart of 13 patients. But, twelve months after the procedure, the small vessels that were formed disappeared. "The first tests were unsuccessful, but today we have the best results for diseases such as Parkinson's disease and leukemia, for example," says Roberto Aguilar, professor of clinical research at the Institute of science, technology and quality (ICTQ) and Director of clinical research at RDO R & d.
apos a transferencia dos direitos da marca por outra empresa, no caso a Merck,Sharp & Dohme Farmaceutica Ltda"Fonte: site da ANVISAOBS: A validade do registro e ate 09/2013, por isso o renovacao do registro devera ser requerida em breve!
the Southeast leads the ranking (29,360), followed by the South (9,350), northeast (8,970), Midwest (3,470) and North (1,530).In relation to the deaths by disease, the most recent that the Inca have is 2010, registered in the database of the single health system (Datasus), with women and 147 12,705 deaths of men only on the public network.Female literacy, behind this type of tumor, in number of diagnoses, the cervix, with new cases referred to 2012 17,540. Among all types of cancer in the prostate, Brazil still reaches more men than breast affects women, according to the Inca. Although the prostate being the most frequent problem in men, with new cases referred to 60,180 this year, lung cancer kills more.Cases of cancer in women in Brazil *Mama-52,680Cervix-17,540Colon and rectum-15,960Thyroid-10,590Trachea, bronchi and lungs-10,110Most cancers that kill women in Brazil **Mama-12,705Trachea, bronchi and lungs-8,190Colon, rectum and anus 6,892Stomach-4,768Pancreas-3,769* Estimates for 2012** 2010 data SUS
the virus triggered an immune response that prevented the development of the flu.For the infectious Charlemagne Fortaleza, a professor at Universidade Estadual Paulista (UNESP), it is important to increase the arsenal of conduct for the prevention and treatment of influenza, now composed of the vaccine and the antivirals oseltamivir and zanamivir. "If you discover a substance that has the potential to enhance immune responses against influenza, it is extremely welcome," he says.The body has two types of immune response: innate and adaptive. While the innate response against the invading generalized manner, the adaptive response involves the production of specific antibodies to combat bacteria or viruses. The study evaluated substance acts directly on the innate immune response, so it would be able to defeat all types of influenza viruses.The EP67 was created to mimic the activity of C5a molecule, which is part of the complement system, one arm of the immune system. Researchers in the protein injected mice that had previously been infected with influenza virus. When administered 24 hours after infection, the protein prevented the development of attenuated or flu symptoms.The parameter for determining the severity of symptoms was weight loss due to the flu.The study, released yesterday in the journal PLoS ONE, also found that the substance prevented the death of mice receiving lethal doses of virus.Prevention. The idea is to develop a drug which may be administered after the patient is exposed to a situation in which the influenza virus is present. To Joy Phillips, a researcher at San Diego State University and an author of the study, the drug would be a trump card for cases where the person who did not take the vaccine is exposed to the virus. The feature would be especially useful for elderly, children, pregnant women and immunosuppressed."The flu virus is sneaky and prevents the immune system to detect it for a few days until it begins to experience symptoms. When you discover that was exposed to the flu, the only treatments currently available vie the virus directly, but not are reliable. And often the virus develops resistance to them, "says Joy.The researcher Thiago Moreno, Oswaldo Cruz Institute, notes that the results should be viewed with caution, as showing that the substance would be effective only if administered within 24 hours after exposure. "If you were thinking of a drug for therapeutic use, when the symptoms appear, usually the patient is already infected a few days ago," he says.
Fonte/Source: FERNANDA BASSETTE - O Estado de S.PauloEngenheiro abandona emprego, estuda literatura medica por conta propria e descobre formula para produzir enzima que retarda evolucao da doenca do filho Entre abril de 1999 e maio de 2000, o engenheiro mecanico Adolfo Celso Guidi, de 54 anos, abriu mao de sua vida pessoal, separou-se da mulher, abandonou o emprego e se enfurnou na biblioteca da Universidade Federal do Parana (UFPR), onde se debrucou sobre livros de medicina. O objetivo era nobre e urgente: Adolfo corria contra o tempo para entender o mecanismo de acao da gangliosidose do tipo 2, doenca genetica rara, neurodegenerativa e sem cura, que havia sido recem-diagnosticada em seu filho, Vitor, que na epoca tinha apenas 10 anos. Descrentes, os medicos deram mais um ano de vida ao menino. E Guidi conseguiu. Sozinho, depois de ler mais de 30 livros de medicina - incluindo areas sobre genetica, neurologia e fisiologia -, ele nao apenas entendeu como a doenca agia no organismo de seu filho, mas descobriu uma formula que retardou sua evolucao. Contrariando a literatura medica - que aponta 11 anos de vida aos portadores de gangliosidose tipo 2 -, Vitor esta vivo e hoje tem 23 anos.O comeco. Vitor foi uma crianca normal, saudavel e ativa ate os seus 4 anos. Precoce, ele deu os primeiros passos sem nem mesmo engatinhar. Aos 4 anos e meio, porem, passou a apresentar os primeiros sinais degenerativos: nao conseguia mais segurar o lapis. Foi perdendo a forca e a coordenacao motora fina. E so piorou.Na escola, a professora dizia que Vitor atrapalhava a aula. Suspeitaram de deficit de atencao. Os pais o mudaram de escola e o mandaram para a terapia. Aos 5 anos, Vitor foi matriculado em uma escola especial - ja nao era mais aceito em escolas comuns.Os sintomas continuaram se agravando, e Vitor ja nao tinha mais coordenacao motora. Aos 8, teve sua primeira crise grave, durante um passeio no shopping. Levado as pressas ao hospital, nao respondia aos estimulos de dor nem de acuidade visual. "Ele nao sentia nada. Depois, eu soube que foi a primeira grande perda neuronal que ele sofreu."A familia foi orientada a procurar ajuda nos EUA, mas, sem dinheiro para isso, a saida foi enviar amostras de material genetico ao exterior em busca de respostas que jamais vieram, pois as desconfiancas dos medicos nunca eram confirmadas.O diagnostico. Adolfo decidiu, entao, viajar com o filho a Argentina para consultar um dos maiores especialistas em genetica do mundo. Ficaram la por uma semana, fizeram uma serie de exames de sangue, de urina, de imagem. Tudo com o dinheiro da rescisao - ele era gerente de uma concessionaria. "Tinha um emprego bom e umas economias. Raspei tudo e gastei cerca de US$ 65 mil. So um dos exames custou US$ 5 mil", conta.O resultado veio em tres semanas: Vitor tinha gangliosidose tipo 2, doenca que, entre outras coisas, provoca defeitos em um tipo de enzima que nao degrada um lipidio que deveria ser naturalmente eliminado pelo corpo, provocando um acumulo prejudicial.De tao raro, o caso de Vitor
foi debatido em congressos. Os exames foram refeitos. E o prognostico era realmente desanimador. "Os medicos disseram que, pelas estatisticas, Vitor teria menos de um ano de vida. Como eu viveria dali para a frente sabendo que meu filho iria morrer?"Inconformado com a possibilidade da perda, Adolfo decidiu estudar a fundo a doenca - que ate entao nao tinha tratamento. Foi nessa epoca que ele passou a frequentar a biblioteca da UFPR diariamente. E, num livro sobre fisiologia clinica, Adolfo encontrou referencias a doenca de Tay-Sachs - muito parecida com a gangliosidose, o que o fez entender o mal que acometia seu filho. "Entendi o mecanismo de acao. Mas e dai? O que fazer com aquilo?"Creme de sorvete. A partir disso, Adolfo percebeu que a doenca tinha relacao com a enzima beta-galactosidase, que era produzida pelo corpo de Vitor de maneira deficiente. Ele passou a ler livros sobre enzimologia. E descobriu que essa enzima foi utilizada na fabricacao de cremes para sorvetes na decada de 1950, mas teria caido em desuso porque surgiram os cremes sinteticos. Ele precisava dessa materia-prima para pensar num possivel medicamento. Disparou e-mails para dezenas de laboratorios do mundo todo que chegaram a produzir essa enzima no passado. Escreveu para Japao, Canada, EUA, Mexico, India, Espanha. Expos seu caso para varios medicos, mas nao conseguia apoio de nenhum deles para a ideia, que parecia maluca. "Ninguem me dava atencao. Diziam que era loucura minha", relembra.Os meses passaram, e a sorte se voltou para Adolfo. A pediatra de Vitor ligou para ele, dizendo que o pai de um paciente era funcionario de um laboratorio e iria ajuda-lo a conseguir a enzima. "Passei um fax com a ficha tecnica. Pouco tempo depois, a matriz me enviou uma amostra de 50 ml da enzima."Uma gota. Com a materia-prima em maos, Adolfo foi a uma farmacia de homeopatia, que com uma unica gota da enzima desenvolveu uma matriz e um "medicamento" para ser tomado diariamente pelo menino. "Ainda assim, os medicos eram contra. Diziam que eu ia matar meu filho." O medo de efeitos colaterais mais serios fez Adolfo tomar o produto varias vezes antes de oferecer a Vitor. "Fui a cobaia." O menino comecou, entao, a tomar as gotas e, quase como num milagre, a doenca deixou de progredir de forma tao agressiva.Vitor parou de andar aos 15 anos. Hoje, caminha quando e escorado pelos bracos do pai. Ele nao fala, mas e capaz de conversar com o pai por meio de gestos e sons. "Ele entende e leva as pessoas a entenderem o que quer." Na escola, reaprendeu coisas basicas, como tirar e colocar os sapatos e escovar os dentes.Nesse periodo, Adolfo quase perdeu a casa - ele deixou de pagar as prestacoes porque gastou o dinheiro no tratamento de Vitor - e ficou sem carro. Nao voltou a trabalhar e vive em funcao do filho, com ajuda de doacoes. Adaptou a cadeira de rodas de Vitor a sua moto: e assim que o leva a escola, a terapia, aos medicos. A evolucao inesperada do jovem fez com que outras
familias procurassem Adolfo em busca do "medicamento" que ele tinha descoberto, mesmo sem comprovacao cientifica. "Ate hoje, ninguem conseguiu rebater minha teoria sobre a eficacia do produto. Fiz pelo Vitor o que qualquer pai faria_______________________________________________________________________________Engineer job, studying medical literature left on their own and discovers formula to produce enzyme that slows development of child disease.Between April 1999 and May 2000, the mechanical engineer Adolfo Celso Guidi, 54 years, gave up his personal life, separated from woman, abandoned the job and if enfurnou in the library of the Federal University of Parana (UFPR) in Brazil, where they discussed medical books. The aim was noble and urgent: Adolfo ran out of time to understand the mechanism of action of 2-type gangliosidosis, rare genetic disease, degenerative and incurable, which had been newly identified in his son, Victor, who at the time was only 10 years. Unbelievers, the doctors gave one more year of life to the boy. And Guidi. Alone, after reading more than 30 medical textbooks-including areas about genetics, Neurology and Physiology he not only understood as agia in the body of his son, but discovered a formula that slowed its evolution. Contrary to the medical literature-that points 11 years of life to patients with 2 type gangliosidosis, Vitor is alive and today has 23 years.The beginning. Vitor was a normal child, healthy and active until your 4 years. Early on, he took the first steps without even crawl. To 4 and a half years, however, began to show the first signs of degenerative: could no longer hold the pencil. Was losing strength and fine motor coordination. And only got worse.At school, the teacher said that Vitor fumbled the classroom. Suspected attention deficit. The parents changed their school and sent for therapy. To 5 years, Victor was enrolled in a special school-was no longer accepted in common schools.The symptoms continued worsening, and Vitor had no more motor coordination. To 8, had its first serious crisis, during a walk in the Mall. Rushed to the hospital, did not respond to pain stimuli or visual acuity. "He felt nothing. Later, I learned that it was the first major neuronal loss that he suffered. "The family was driven to seek help in the USA, but no money for this, the output was send samples of genetic material to the outside world in search of answers that never came, because the mistrust of doctors never were confirmed.The diagnosis. Adolfo then decided to travel with the child to Argentina to see one of the world's leading specialists in genetics. Stayed there for a week, made a series of blood tests, urine tests, Imaging. All the money from termination-he was Manager of a dealership. "Had a good job and savings. Shaved everything and spent about R$ 65,000. Only one of the exams cost R$ 5,000, "he says.The result came in three weeks: Vitor had 2 type gangliosidosis, disease which, among other things, causes defects in a type of enzyme that breaks down a lipid that should be eliminated naturally by the body, causing a harmful accumulation.So rare, the case of
Vitor was debated in Congress. The examinations were redone. And the prognosis was disheartening really. "The doctors said that, by statistics, Vitor would have less than a year of life. As I live from there forward knowing that my son would die? "Unhappy with the possibility of loss, Adolfo decided to study in depth the disease-which until then had no treatment. It was at this time that he began to frequent the library of UFPR daily. And, in a book about Clinical Physiology, Adolfo found references to Tay-Sachs disease-much like the gangliosidosis, what did understand the evil that the Villa wahnfried his son. "I understand the mechanism of action. But so what? What to do with it? "Ice Cream. From this, Adolfo realized that the disease had a relationship with the enzyme beta-galactosidase, which was produced by Vitor poorly. He went on to read books on enzymology. And found that this enzyme was used in the manufacture of ice creams in the Decade of 1950, but have fallen into disuse because synthetic creams emerged. He needed this raw material to think about a possible medicine. Triggered emails to dozens of labs around the world who came to produce this enzyme in the past. Wrote to Japan, Canada, USA, Mexico, India, Spain. He exhibited his case for several doctors, but could not support any of them for the idea, which seemed crazy. "Nobody gave me attention. Said it was my madness, "he recalls.The months passed, and the luck turned to Adolfo. The Vitor's pediatrician called him, saying that the father of a patient was an employee of a lab and would help him achieve the enzyme. "I spent a fax with the sheet. Shortly thereafter, the array sent me a sample of 50 ml of enzyme. "A drop. With the raw material at hand, Adolfo was to a pharmacy of homeopathy, that with a single drop of the enzyme developed a matrix and a "medicine" to be taken daily by the boy. "Still, the doctors were against. They said that I was going to kill my son. " The fear of serious side effects made Adolfo taking the product several times before offering to Vitor. "I was the Guinea pig." The boy began then to take the drops and, almost as a miracle, the disease was progressing so aggressively.Vitor stopped walking to 15 years. Today, walks when it is anchored by the arms of the father. He does not speak, but is able to converse with the father through gestures and sounds. "He understands and takes people to understand what they want." In school, basic things, like taking relearned and put the shoes and brushing your teeth.During this period, Adolfo almost missed the House-he failed to pay the benefits because they spent the money on treatment of Vitor-and ran out of the car. Has not returned to work and live in the light of the son, with the help of donations. Wheelchair adapted to your bike: Vitor is so takes you to school, therapy, physicians. The unexpected development of the young has made
other families seek Adolfo in search of "medicine" that he had discovered, even without scientific proof. "Until today, no one managed to hit my theory about the efficacy of the product. Made by Vitor what any parent would do. "
desabastecimento. Novo pregao foi realizado, desta vez com sucesso, e a previsao e de que a situacao esteja normalizada nas proximas semanas, afirmou a secretaria, em nota.Segundo o medico Carmino Antonio de Souza, presidente da ABHH, a interrupcao do tratamento, teoricamente, e prejudicial. Hoje esta demonstrado cientificamente, ate temos um trabalho mostrando isso, que a aderencia ao tratamento e o ponto critico na resposta. Aqueles que tem acima de 96% de aderencia tem uma evolucao muito melhor que os de baixa aderencia, com menos de 80%. As informacoes sao do jornal O Estado de S. PauloVEJA A PARTE 2, AQUI!